Demand is Outpacing Supply.....
Leer Target for ---TTHI ---us$21---OutPerform
Transitions Business Model is Evolving into an Inhouse R&D Bio after growing significantly from its 2001 IPO and 6 Years of Buy and Build Growth.
IMO Dr. Cruz's most significant purchase was in Bankruptcy Court for the Optimol Technology. Transitions Proprietary State-of-the Art Drug Discovery Engine and extensive drug development program is finding novel therapeutics in multiple disease indications. Not to mention it was put to use to help validate AZD-103 and is mtl as we speak being used to check out 'Minozac'. Its expected that 'Minozac' will be useful in a variety of diseases and this technology will help 'Minozac' in that endeavour by finding different disease targets.
Challenges Facing
Buy & Build Companies---
"Identifying attractive compounds for
in-licensing is becoming more difficult
because demand is outpacing supply. While
the number of INDs has remained steady
throughout the past decade, they have failed
to keep pace with the increasing demand
for attractive compounds. Biotechnology
companies looking to fill development gaps
through in-licensing, lack of productivity
from Big Pharma, and competitive
pressures from the increasing number of
Buy & Build companies has strained the
supply of high potential compounds. As
these challenges are likely to increase, the
ability to secure high-potential sources of
innovation through in-licensing will
continue to become more difficult."
Transitions robust and advancing Pipeline will have no problem filling in any gaps left by abandoned or failed drugs. HepC still not partnered will be replaced eventually by any of a multitude of Drugs should it come to that. Longs understand this and are reminded by Dr. Cruz whenever he talks about the Business Model.
Others that have Modeled themselves as Buy and Build Co's will suffer eventually due in no small part to Higher Cost of In-licensing agreements and Stiff Competition for available High Potential Drugs.........like we saw with AZD-103 and our us$200 Million WWCA with Elan.
I for one am glad we're morphing into a Fully Integrated In-House R&D Biotech with a Proprietary State of the Art Drug Discovery Division. The Recruitment for an Associate Director of Preclinical Research underscores Transitions committment to advancing in Pre-Clinical to keep pace with Clinical Trials that are just ramping up here!
GLA
!!The Excitement Awards!! Thursday every week.